title: [Paradoxical cutaneous reactions associated with tocilizumab therapy].
abstract: BACKGROUND
  Tocilizumab (TCZ) is a humanized antihuman interleukin (IL)-6 receptor antibody recommended for the treatment of moderate to severe active rheumatoid arthritis, adult-onset Still disease, Castleman disease and more recently, systemic juvenile idiopathic arthritis. Like anti-TNFα, rituximab and less frequently abatacept, TCZ can induce paradoxical cutaneous eruption like psoriasis with predominantly palmoplantar presentation.
  
  
  METHODS
  We report a 47-year-old woman with psoriastic arthritis who developed under anti-TNFα therapy and later under tocilizumab a paradoxical palmoplantar eruption.
  
  
  CONCLUSIONS
  The specific underlying mechanisms of this side effect are unclear but relapse of these lesions seems to be observed with certain biological agents.
authors.affiliation: Service de rhumatologie, hôpital Émile-Muller, centre hospitalier de Mulhouse, 20, avenue du Docteur-Laennec, 68100 Mulhouse, France. Electronic address: sparsal@ch-mulhouse.fr.
authors.forename: L
authors.initials: L
authors.lastname: Sparsa
authors.affiliation: Service de rhumatologie, hôpital Émile-Muller, centre hospitalier de Mulhouse, 20, avenue du Docteur-Laennec, 68100 Mulhouse, France.
authors.forename: N
authors.initials: N
authors.lastname: Afif
authors.affiliation: Service de dermatologie, centre hospitalier de Mulhouse, hôpital Émile-Muller, centre hospitalier de Mulhouse, 20, avenue du Docteur-Laennec, 68100 Mulhouse, France.
authors.forename: S
authors.initials: S
authors.lastname: Bularca
authors.affiliation: Service de pathologie, centre hospitalier de Mulhouse, hôpital Émile-Muller, centre hospitalier de Mulhouse, 20, avenue du Docteur-Laennec, 68100 Mulhouse, France.
authors.forename: A
authors.initials: A
authors.lastname: Fricker
authors.affiliation: Service de pathologie, centre hospitalier de Mulhouse, hôpital Émile-Muller, centre hospitalier de Mulhouse, 20, avenue du Docteur-Laennec, 68100 Mulhouse, France.
authors.forename: S
authors.initials: S
authors.lastname: Thiebault
authors.affiliation: Service de rhumatologie, hôpital Émile-Muller, centre hospitalier de Mulhouse, 20, avenue du Docteur-Laennec, 68100 Mulhouse, France.
authors.forename: E
authors.initials: E
authors.lastname: Dahan
authors.affiliation: Service de rhumatologie, hôpital Jean Minjoz, CHRU de Besançon, 2, boulevard Fleming, 25030 Besançon, France.
authors.forename: D
authors.initials: D
authors.lastname: Wendling
authors.affiliation: Service de rhumatologie, hôpital de Hautepierre, CHU de Strasbourg, 1, avenue Molière, 67098 Strasbourg France.
authors.forename: J
authors.initials: J
authors.lastname: Sibilia
authors.affiliation: Service de rhumatologie, hôpital Émile-Muller, centre hospitalier de Mulhouse, 20, avenue du Docteur-Laennec, 68100 Mulhouse, France.
authors.forename: M
authors.initials: M
authors.lastname: Ardizzone
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D003875:Drug Eruptions / Q000175:diagnosis*; D005260:Female; D006801:Humans; D008875:Middle Aged
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C502936:tocilizumab
keywords: Effet paradoxal; Paradoxical effect; Polyarthrite rhumatoïde; Psoriatic arthritis; Rheumatoid arthritis; Rhumatisme psoriasique; Tocilizumab